


Figure 1



= SOLID SUPPORT

R = TERMINAL PROTECTING GROUP

FOR EXAMPLE:

DIMETHOXYTRITYL (DMT)



⁽¹⁾
~~~~~ = CLEAVABLE LINKER

(FOR EXAMPLE: NUCLEOTIDE SUCCINATE OR




INVERTED DEOXYABASIC SUCCINATE)


<sup>(2)</sup>  
~~~~~ = CLEAVABLE LINKER

(FOR EXAMPLE: NUCLEOTIDE SUCCINATE OR

INVERTED DEOXYABASIC SUCCINATE)



INVERTED DEOXYABASIC SUCCINATE
LINKAGE



GLYCERYL SUCCINATE LINKAGE

Figure 2




Figure 3





Figure 4




POSITIONS (NN) CAN COMprise ANY NUCLEOTIDE, SUCH AS DEOXYNUCLEOTIDES (eg. THYMIDINE) OR UNIVERSAL BASES

B = ABASIC, INVERTED ABASIC, INVERTED NUCLEOTIDE OR OTHER TERMINAL CAP THAT IS OPTIONAL LY PRESENT

L = GLYCERYL MOIETY THAT IS OPTIONAL Y PRESENT

L = GETCERYL MOIETY THAT IS OPTIONALLY PRESENT
S = PHOSPHOROTHIOATE OR PHOSPHORODITHIOATE

Figure 5



lower case = 2'-O-Methyl or 2'-deoxy-2'-fluoro
italic lower case = 2'-deoxy-2'-fluoro
underline = 2'-O-methyl

ITALIC UPPER CASE = DEOXY
 B = INVERTED DEOXYABASIC
 L = GLYCERYL MOIETY OPTIONAL PRESENT
 S = PHOSPHOROTHIOATE OR
 PHOSPHORODITHIOATE

Figure 6




Figure 7




Figure 8




Figure 9: Target site Selection using siRNA





Figure 10



$\text{R} = \text{O, S, N, alkyl, substituted alkyl, O-alkyl, S-alkyl, alkaryl, or aralkyl}$
 $\text{B} = \text{Independently any nucleotide base, either naturally occurring or chemically modified, or optionally H (abasic).}$

Figure 11: Modification Strategy





Figure 12: Inhibition of VEGF-Induced Angiogenesis by siRNAs






Figure 14: Phosphorylated siNA constructs




Figure 15: 5'-phosphate modifications






Figure 16: siNA Targeting VEGFR-1 Inhibits VEGF-Induced Rat Corneal Angiogenesis



**Figure 17: Inhibition of Mouse CNV with
anti-VEGFR-1 siNA (intraocular administration)**
57% inhibition at 1.5 μ g vs inverted control



**Figure 18: Inhibition of Mouse CNV with
anti-VEGFR-1 siNA (periocular administration)**




Figure 19: Inhibition of Mouse CNV with anti-VEGFR-1 siRNA (periocular administration)

